Effect of switching administration of alendronate after teriparatide for the prevention of BMD loss around the implant after total hip arthroplasty, 2-year follow-up: a randomized controlled trial

What Was Tested

This randomized controlled trial paper looks at Teriparatide.

The aim of this study is that changes in BMD is compared in patients switched from teriparatide to alendronate, in patients treated with alendronate alone, and in control patients without medication after total hip arthroplasty.

Why It Was Studied

Stress shielding after total hip arthroplasty (THA) can induce bone mineral density (BMD) loss around the femoral implant.

Who Took Part

PubMed indexes the participants as middle-aged adults and older adults, both men and women.

Baseline periprosthetic BMD was measured by dual-energy X-ray absorptiometry (DEXA) 1 week after THA, followed by subsequent measurements at 1 and 2 years postoperatively.

How the Study Was Run

The researchers set it up as a randomized study.

Because people in this Teriparatide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Lumbar BMD was also evaluated at preoperatively, 1 and 2 years postoperatively.

What Was Measured

Topics PubMed links to this paper include Alendronate, Arthroplasty, Replacement, Hip, Bone Density, Bone Density Conservation Agents, Bone Resorption, Postoperative Complications and Teriparatide.

Author keywords: Alendronate (ALD), Bone mineral density (BMD) and Total hip arthroplasty (THA).

What This Means in Plain Language

The paper is a randomized study of Teriparatide.

Results are reported in around 6 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2020 (Journal of orthopaedic surgery and research), a journal based in England.

More context: the Teriparatide compound page, all human trials.